This is a Wow. Pancreatic cancer used to be a brutal death sentence

Faster than expected FDA approval for NVCR shows the need. Even with the rally, $1.5bb cap is far too low. Two months additional life is meaningful.

Bloomberg) -- Novocure shares gain as much as 34% in

premarket trading on Thursday after the oncology company

announced the US FDA approved its wearable medical device Optune

Pax for treating locally advanced pancreatic cancer when used

with gemcitabine and nab-paclitaxel chemotherapy. Analysts note

that the approval came in earlier than expected.